Cargando…
Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021
Pediatric tinea capitis displays a wide range of prevalence, with significant variability among populations. We retrospectively extracted the medical records of 456 pediatric patients diagnosed with tinea capitis during the years 2010–2021, from the dermatology outpatient clinics in two tertiary med...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054890/ https://www.ncbi.nlm.nih.gov/pubmed/36983534 http://dx.doi.org/10.3390/jof9030366 |
_version_ | 1785015780791812096 |
---|---|
author | Dascalu, Joel Zaaroura, Hiba Renert-Yuval, Yael Khamaysi, Ziyad Avitan-Hersh, Emily Friedland, Rivka |
author_facet | Dascalu, Joel Zaaroura, Hiba Renert-Yuval, Yael Khamaysi, Ziyad Avitan-Hersh, Emily Friedland, Rivka |
author_sort | Dascalu, Joel |
collection | PubMed |
description | Pediatric tinea capitis displays a wide range of prevalence, with significant variability among populations. We retrospectively extracted the medical records of 456 pediatric patients diagnosed with tinea capitis during the years 2010–2021, from the dermatology outpatient clinics in two tertiary medical centers. Three species were isolated in 90% of patients: T. tonsurans, M. canis, and T. violaceum. While T. tonsurans presented a six-fold increase in incidence during the years 2019–2021, M. canis maintained stable incidence rates. Furthermore, terbinafine was the most efficient antifungal agent against T. tonsurans, achieving complete clinical clearance in 95% of patients, as compared to fluconazole (68%) and griseofulvin (38%) (p < 0.001). The mycological cure was recorded in 61/90 (68%) of patients with available data, at an average of 10 weeks. For patients with M. canis, griseofulvin and fluconazole were equally efficient (73% and 66%, respectively) (p = 0.44). Kerion was described in 36% and 14% of patients with T. tonsurans and M. canis, respectively, (p < 0.001). In conclusion, since 2019, there has been a significant increase in the prevalence of T. tonsurans, establishing this pathogen as the most common cause for tinea capitis in our population. Our data suggest that terbinafine is effective and presents high cure rates for tinea capitis in the pediatric population. |
format | Online Article Text |
id | pubmed-10054890 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100548902023-03-30 Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021 Dascalu, Joel Zaaroura, Hiba Renert-Yuval, Yael Khamaysi, Ziyad Avitan-Hersh, Emily Friedland, Rivka J Fungi (Basel) Article Pediatric tinea capitis displays a wide range of prevalence, with significant variability among populations. We retrospectively extracted the medical records of 456 pediatric patients diagnosed with tinea capitis during the years 2010–2021, from the dermatology outpatient clinics in two tertiary medical centers. Three species were isolated in 90% of patients: T. tonsurans, M. canis, and T. violaceum. While T. tonsurans presented a six-fold increase in incidence during the years 2019–2021, M. canis maintained stable incidence rates. Furthermore, terbinafine was the most efficient antifungal agent against T. tonsurans, achieving complete clinical clearance in 95% of patients, as compared to fluconazole (68%) and griseofulvin (38%) (p < 0.001). The mycological cure was recorded in 61/90 (68%) of patients with available data, at an average of 10 weeks. For patients with M. canis, griseofulvin and fluconazole were equally efficient (73% and 66%, respectively) (p = 0.44). Kerion was described in 36% and 14% of patients with T. tonsurans and M. canis, respectively, (p < 0.001). In conclusion, since 2019, there has been a significant increase in the prevalence of T. tonsurans, establishing this pathogen as the most common cause for tinea capitis in our population. Our data suggest that terbinafine is effective and presents high cure rates for tinea capitis in the pediatric population. MDPI 2023-03-17 /pmc/articles/PMC10054890/ /pubmed/36983534 http://dx.doi.org/10.3390/jof9030366 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Dascalu, Joel Zaaroura, Hiba Renert-Yuval, Yael Khamaysi, Ziyad Avitan-Hersh, Emily Friedland, Rivka Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021 |
title | Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021 |
title_full | Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021 |
title_fullStr | Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021 |
title_full_unstemmed | Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021 |
title_short | Pediatric Tinea Capitis: A Retrospective Cohort Study from 2010 to 2021 |
title_sort | pediatric tinea capitis: a retrospective cohort study from 2010 to 2021 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10054890/ https://www.ncbi.nlm.nih.gov/pubmed/36983534 http://dx.doi.org/10.3390/jof9030366 |
work_keys_str_mv | AT dascalujoel pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021 AT zaarourahiba pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021 AT renertyuvalyael pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021 AT khamaysiziyad pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021 AT avitanhershemily pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021 AT friedlandrivka pediatrictineacapitisaretrospectivecohortstudyfrom2010to2021 |